Anne-Mette Bjerregaard

Anne-Mette Bjerregaard

Auto-generated profile, based on publicly available information

Anne-Mette Bjerregaard

Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ABAnne-Mette Bjerregaard
Anne-Mette Bjerregaard
MNMorten Nielsen
Morten Nielsen
SHSine Reker Hadrup
Sine Reker Hadrup
ZSZoltan Szallasi
Zoltan Szallasi
AEAron Charles Eklund
Aron Charles Eklund

18 January 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NKNikolaj Pagh Kristensen
Nikolaj Pagh Kristensen
CHChristina Heeke
Christina Heeke
STSiri A. Tvingsholm
Siri A. Tvingsholm
ABAnnie Borch
Annie Borch
ADArianna Draghi
Arianna Draghi
SHSine Reker Hadrup
Sine Reker Hadrup
BACKGROUND. Neoantigen-driven recognition and T cell–mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined. METHODS. Using barcoded pMHC multimers, we provide a comprehensive mapping of CD8+ T cells recognizing neoepitopes in TIL infusion products and blood samples from 26 metastatic melanoma patients who received ACT. RESULTS. We identified 106 neoepitopes within TIL infusion products corresponding to 1.8% of all predicted neoepitopes. We observed neoepitope-specific recognition to be virtually devoid in TIL infusion products given to patients with progressive disease outcome. Moreover, we found that the frequency of neoepitope-specific CD8+ T cells in TIL infusion products correlated with increased survival and that neoepitope-specific CD8+ T cells shared with the infusion product in posttreatment blood samples were unique to responders of TIL-ACT. Finally, we found that a transcriptional signature for lymphocyte activity within the tumor microenvironment was associated with a higher frequency of neoepitope-specific CD8+ T cells in the infusion product. CONCLUSIONS. These data support previous case studies of neoepitope-specific CD8+ T cells in melanoma and indicate that successful TIL-ACT is associated with an expansion of neoepitope-specific CD8+ T cells. FUNDING. NEYE Foundation; European Research Council; Lundbeck Foundation Fellowship; Carlsberg Foundation.

15 November 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
ABAnne-Mette Bjerregaard
Anne-Mette Bjerregaard
MNMorten Nielsen
Morten Nielsen
VJVanessa Jurtz
Vanessa Jurtz
CBCarolina M. Barra
Carolina M. Barra
SHSine Reker Hadrup
Sine Reker Hadrup
AEAron Charles Eklund
Aron Charles Eklund
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy may benefit from efficient identification and targeting of patient-specific neoepitopes. However, current neoepitope prediction methods based on sequencing and predictions of epitope processing and presentation result in a low rate of validation, suggesting that the determinants of peptide immunogenicity are not well understood. We gathered published data on human neopeptides originating from single amino acid substitutions for which T cell reactivity had been experimentally tested, including both immunogenic and non-immunogenic neopeptides. Out of 1,948 neopeptide-HLA (human leukocyte antigen) combinations from 13 publications, 53 were reported to elicit a T cell response. From these data, we found an enrichment for responses among peptides of length 9. Even though the peptides had been pre-selected based on presumed likelihood of being immunogenic, we found using NetMHCpan-4.0 that immunogenic neopeptides were predicted to bind significantly more strongly to HLA compared to non-immunogenic peptides. Investigation of the HLA binding strength of the immunogenic peptides revealed that the vast majority (96%) shared very strong predicted binding to HLA and that the binding strength was comparable to that observed for pathogen-derived epitopes. Finally, we found that neopeptide dissimilarity to self is a predictor of immunogenicity in situations where neo- and normal peptides share comparable predicted binding strength. In conclusion, these results suggest new strategies for prioritization of mutated peptides, but new data will be needed to confirm their value.

19 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NPNatasja Wulff Pedersen
Natasja Wulff Pedersen
AHAnja Holm
Anja Holm
NKNikolaj Pagh Kristensen
Nikolaj Pagh Kristensen
ABAnne-Mette Bjerregaard
Anne-Mette Bjerregaard
ABAmalie Kai Bentzen
Amalie Kai Bentzen
BKBirgitte Rahbek Kornum
Birgitte Rahbek Kornum
Narcolepsy Type 1 (NT1) is a neurological sleep disorder, characterized by the loss of hypocretin/orexin signaling in the brain. Genetic, epidemiological and experimental data support the hypothesis that NT1 is a T-cell-mediated autoimmune disease targeting the hypocretin producing neurons. While autoreactive CD4+ T cells have been detected in patients, CD8+ T cells have only been examined to a minor extent. Here we detect CD8+ T cells specific toward narcolepsy-relevant peptides presented primarily by NT1-associated HLA types in the blood of 20 patients with NT1 as well as in 52 healthy controls, using peptide-MHC-I multimers labeled with DNA barcodes. In healthy controls carrying the disease-predisposing HLA-DQB1*06:02 allele, the frequency of autoreactive CD8+ T cells was lower as compared with both NT1 patients and HLA-DQB1*06:02-negative healthy individuals. These findings suggest that a certain level of CD8+ T-cell reactivity combined with HLA-DQB1*06:02 expression is important for NT1 development.

9 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Sunil Kumar SainiSunil Kumar Saini
Sunil Kumar Saini
AØAndreas Due Ørskov
Andreas Due Ørskov
ABAnne-Mette Bjerregaard
Anne-Mette Bjerregaard
AUAshwin Unnikrishnan
Ashwin Unnikrishnan
SHStaffan Holmberg-Thydén
Staffan Holmberg-Thydén
SHSine Reker Hadrup
Sine Reker Hadrup
Human endogenous retroviruses (HERV) form a substantial part of the human genome, but mostly remain transcriptionally silent under strict epigenetic regulation, yet can potentially be reactivated by malignant transformation or epigenetic therapies. Here, we evaluate the potential for T cell recognition of HERV elements in myeloid malignancies by mapping transcribed HERV genes and generating a library of 1169 potential antigenic HERV-derived peptides predicted for presentation by 4 HLA class I molecules. Using DNA barcode-labeled MHC-I multimers, we find CD8+ T cell populations recognizing 29 HERV-derived peptides representing 18 different HERV loci, of which HERVH-5, HERVW-1, and HERVE-3 have more profound responses; such HERV-specific T cells are present in 17 of the 34 patients, but less frequently in healthy donors. Transcriptomic analyses reveal enhanced transcription of the HERVs in patients; meanwhile DNA-demethylating therapy causes a small and heterogeneous enhancement in HERV transcription without altering T cell recognition. Our study thus uncovers T cell recognition of HERVs in myeloid malignancies, thereby implicating HERVs as potential targets for immunotherapeutic therapies.

11 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJeppe Sejerø Holm
Jeppe Sejerø Holm
SFSamuel A. Funt
Samuel A. Funt
ABAnnie Borch
Annie Borch
KMKamilla Kjærgaard Munk
Kamilla Kjærgaard Munk
ABAnne-Mette Bjerregaard
Anne-Mette Bjerregaard
SHSine Reker Hadrup
Sine Reker Hadrup
CD8+ T cell reactivity towards tumor mutation-derived neoantigens is widely believed to facilitate the antitumor immunity induced by immune checkpoint blockade (ICB). Here we show that broadening in the number of neoantigen-reactive CD8+ T cell (NART) populations between pre-treatment to 3-weeks post-treatment distinguishes patients with controlled disease compared to patients with progressive disease in metastatic urothelial carcinoma (mUC) treated with PD-L1-blockade. The longitudinal analysis of peripheral CD8+ T cell recognition of patient-specific neopeptide libraries consisting of DNA barcode-labelled pMHC multimers in a cohort of 24 patients from the clinical trial NCT02108652 also shows that peripheral NARTs derived from patients with disease control are characterised by a PD1+ Ki67+ effector phenotype and increased CD39 levels compared to bystander bulk- and virus-antigen reactive CD8+ T cells. The study provides insights into NART characteristics following ICB and suggests that early-stage NART expansion and activation are associated with response to ICB in patients with mUC.